Catalent (CTLT)
(Delayed Data from NYSE)
$53.58 USD
-0.42 (-0.78%)
Updated May 29, 2024 04:00 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 61 - 80 ( 216 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Sciences: COVID Era Concluding - Mapping Company Exposure
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
FX and COVID Cliffs but Raising LT Guide
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
An Active Pace of Investment - Metric Acquisition Fits - RGEN Combo Seems Unlikely
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
DHR & SRT3: Strong Life Science Earnings Season Begins
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
U.S. COVID-19 Vaccine Order Includes First-Time Single- Dose Format
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
2Q Preview - Mapping COVID Sales; 2023 Visibility Increasing
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Lots of Leading Indicators for Robust Pre-Filled Syringe Demand
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department